TR200101087T2 - İnterferon beta-füzyon proteinleri ve kullanımları - Google Patents
İnterferon beta-füzyon proteinleri ve kullanımlarıInfo
- Publication number
- TR200101087T2 TR200101087T2 TR2001/01087T TR200101087T TR200101087T2 TR 200101087 T2 TR200101087 T2 TR 200101087T2 TR 2001/01087 T TR2001/01087 T TR 2001/01087T TR 200101087 T TR200101087 T TR 200101087T TR 200101087 T2 TR200101087 T2 TR 200101087T2
- Authority
- TR
- Turkey
- Prior art keywords
- interferon
- beta
- fusion proteins
- interferon beta
- glycosyl
- Prior art date
Links
- 102000014150 Interferons Human genes 0.000 title 1
- 108010050904 Interferons Proteins 0.000 title 1
- 229940079322 interferon Drugs 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 125000003147 glycosyl group Chemical group 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 102000003996 Interferon-beta Human genes 0.000 abstract 1
- 108090000467 Interferon-beta Proteins 0.000 abstract 1
- 230000004927 fusion Effects 0.000 abstract 1
- 229960001388 interferon-beta Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/565—IFN-beta
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Abstract
X-Y-Z amino asit dizisini veya bir kismini haiz izole edilmis lbir füzyon polipeptidi tarif edilmistir; glikosil ile birlestirilmis interferon-betanin(X) amino asit dizisini ihtiva eder; Y istege bagli baglanti yapici bir yari moleküldür; ve Z, glikosil ile birlestirilmis interferon beta disinda baska bir polipeptidin len azindan bir kisminda olusan bir polipetittir. X'in insan interferon-beta-la'si olmasi tercih edilir. Interferon-beta-la'nin mutantlari da tarif edilmistir.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10449198P | 1998-10-16 | 1998-10-16 | |
US12023799P | 1999-02-16 | 1999-02-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
TR200101087T2 true TR200101087T2 (tr) | 2001-09-21 |
Family
ID=26801613
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TR2001/01087T TR200101087T2 (tr) | 1998-10-16 | 1999-10-15 | İnterferon beta-füzyon proteinleri ve kullanımları |
Country Status (28)
Country | Link |
---|---|
US (3) | US6800735B2 (tr) |
EP (1) | EP1121382B9 (tr) |
JP (2) | JP4761621B2 (tr) |
KR (1) | KR100767649B1 (tr) |
CN (1) | CN100480266C (tr) |
AT (1) | ATE327254T1 (tr) |
AU (1) | AU766190B2 (tr) |
BR (1) | BR9915548A (tr) |
CA (1) | CA2343094A1 (tr) |
CY (1) | CY1105173T1 (tr) |
CZ (1) | CZ300762B6 (tr) |
DE (1) | DE69931507T2 (tr) |
DK (1) | DK1121382T3 (tr) |
EA (1) | EA005005B1 (tr) |
EE (1) | EE05111B1 (tr) |
ES (1) | ES2265693T3 (tr) |
HK (1) | HK1042098B (tr) |
HU (1) | HUP0200414A2 (tr) |
IL (2) | IL142350A0 (tr) |
IS (1) | IS5887A (tr) |
MX (1) | MXPA01003790A (tr) |
NO (1) | NO20011861L (tr) |
NZ (1) | NZ510559A (tr) |
PL (1) | PL200586B1 (tr) |
PT (1) | PT1121382E (tr) |
SK (1) | SK287491B6 (tr) |
TR (1) | TR200101087T2 (tr) |
WO (1) | WO2000023472A2 (tr) |
Families Citing this family (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1039931T3 (da) * | 1997-12-01 | 2005-08-08 | Fang Fang | Multivalente rekombinante antistoffer til at behandle HRV infektioner |
DK1656952T3 (da) * | 1998-10-16 | 2014-01-20 | Biogen Idec Inc | Polyalkylenglycolkonjugater af interferon beta-1A og anvendelser deraf |
CA2343094A1 (en) * | 1998-10-16 | 2000-04-27 | Biogen, Inc. | Interferon-beta fusion proteins and uses |
US20030035798A1 (en) * | 2000-08-16 | 2003-02-20 | Fang Fang | Humanized antibodies |
US7144574B2 (en) | 1999-08-27 | 2006-12-05 | Maxygen Aps | Interferon β variants and conjugates |
US6531122B1 (en) | 1999-08-27 | 2003-03-11 | Maxygen Aps | Interferon-β variants and conjugates |
US7431921B2 (en) | 2000-04-14 | 2008-10-07 | Maxygen Aps | Interferon beta-like molecules |
US6697363B1 (en) | 2000-06-28 | 2004-02-24 | Alcatel Canada Inc. | Method and apparatus for longest matching prefix determination in a communication network |
AU2002212107A1 (en) * | 2000-11-02 | 2002-05-15 | Maxygen Aps | New multimeric interferon beta polypeptides |
AU2002226366B2 (en) * | 2000-12-06 | 2007-03-22 | Laboratoires Serono Sa | Use of SARP-1 for the treatment and/or prevention of scleroderma |
ATE310092T1 (de) * | 2001-02-01 | 2005-12-15 | Hoffmann La Roche | Verfahren zur herstellung von rekombinantem trypsin |
CA2469846A1 (en) | 2001-02-27 | 2002-09-26 | Maxygen Aps | New interferon beta-like molecules |
WO2002074783A2 (en) * | 2001-03-15 | 2002-09-26 | Merck Patent Gmbh | Modified interferon beta with reduced immunogenicity |
WO2003062370A2 (en) * | 2001-07-19 | 2003-07-31 | Perlan Therapeutics, Inc. | Multimeric proteins and methods of making and using same |
DK1471974T3 (da) * | 2002-02-06 | 2007-12-03 | Ares Trading Sa | Tumornekrose-faktor kombineret med interferon ved demyeliniserende sygdomme |
BR0312947A (pt) * | 2002-07-17 | 2007-07-10 | Biogen Idec Inc | terapias para insuficiência renal empregando-se interferon-beta |
AU2003254641A1 (en) * | 2002-08-28 | 2004-03-19 | Maxygen Aps | Interferon beta-like molecules for treatment of cancer |
ATE466085T1 (de) * | 2002-09-09 | 2010-05-15 | Hanall Pharmaceutical Co Ltd | Protease-resistente modifizierte interferon alpha polypeptide |
GEP20094699B (en) * | 2002-09-27 | 2009-06-10 | Biogen Idec Inc | THERAPIES FOR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY USING ß-INTERFERON |
AU2003277088A1 (en) * | 2002-10-01 | 2004-04-23 | Xencor, Inc | Interferon variants with improved properties |
CA2532966C (en) | 2003-07-15 | 2012-12-04 | Chugai Seiyaku Kabushiki Kaisha | Igm production by transformed cells and methods for quantifying said igm production |
WO2005024044A2 (en) * | 2003-09-05 | 2005-03-17 | Gtc Biotherapeutics, Inc. | Method for the production of fusion proteins in transgenic mammal milk |
WO2005035574A1 (ja) | 2003-10-09 | 2005-04-21 | Chugai Seiyaku Kabushiki Kaisha | IgM高濃度安定化溶液 |
ES2378167T3 (es) | 2003-11-13 | 2012-04-09 | Hanmi Holdings Co., Ltd | Complejo de proteína que utiliza fragmento de inmunoglobulina y el método para su preparación |
US8110665B2 (en) | 2003-11-13 | 2012-02-07 | Hanmi Holdings Co., Ltd. | Pharmaceutical composition comprising an immunoglobulin FC region as a carrier |
JP4896745B2 (ja) | 2004-02-02 | 2012-03-14 | アンブレツクス・インコーポレイテツド | 修飾されたヒトインターフェロンポリペプチドおよびこれらの使用 |
CA2556339A1 (en) * | 2004-03-01 | 2005-09-15 | David Ray Filpula | Interferon-beta polymer conjugates |
US20050276785A1 (en) * | 2004-06-09 | 2005-12-15 | Schering Aktiengesellschaft | Treatment of cardiomyopathy and of endothelial dysfunction |
US7670595B2 (en) * | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
CN107028760B (zh) * | 2005-01-12 | 2019-11-01 | 比奥根Ma公司 | 运输干扰素-β的方法 |
KR20080050591A (ko) | 2005-09-01 | 2008-06-09 | 아레스 트레이딩 에스.에이. | 시신경염 치료 |
US9249407B2 (en) | 2006-02-03 | 2016-02-02 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
US9458444B2 (en) | 2006-02-03 | 2016-10-04 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
US10221228B2 (en) | 2006-02-03 | 2019-03-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
US8759292B2 (en) | 2006-02-03 | 2014-06-24 | Prolor Biotech, Llc | Long-acting coagulation factors and methods of producing same |
WO2007092252A2 (en) * | 2006-02-03 | 2007-08-16 | Modigene Inc | Long-acting polypeptides and methods of producing same |
US10351615B2 (en) | 2006-02-03 | 2019-07-16 | Opko Biologics Ltd. | Methods of treatment with long-acting growth hormone |
US20140113860A1 (en) | 2006-02-03 | 2014-04-24 | Prolor Biotech Ltd. | Long-acting polypeptides and methods of producing and administering same |
US8476234B2 (en) | 2006-02-03 | 2013-07-02 | Prolor Biotech Inc. | Long-acting coagulation factors and methods of producing same |
US20150038413A1 (en) | 2006-02-03 | 2015-02-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
US8048849B2 (en) | 2006-02-03 | 2011-11-01 | Modigene, Inc. | Long-acting polypeptides and methods of producing same |
US8450269B2 (en) | 2006-02-03 | 2013-05-28 | Prolor Biotech Ltd. | Long-acting growth hormone and methods of producing same |
US8946155B2 (en) | 2006-02-03 | 2015-02-03 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
US20080003202A1 (en) * | 2006-03-28 | 2008-01-03 | Thierry Guyon | Modified interferon-beta (IFN-beta) polypeptides |
JO3324B1 (ar) | 2006-04-21 | 2019-03-13 | Amgen Inc | مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية |
JP2009537605A (ja) | 2006-05-24 | 2009-10-29 | メルク セローノ ソシエテ アノニム | 多発性硬化症を治療するためのクラドリビン・レジメン |
US8414897B1 (en) * | 2006-10-02 | 2013-04-09 | The Uab Research Foundation | Pathway for Th-17 cell development and methods utilizing same |
FR2907454B1 (fr) * | 2006-10-18 | 2009-01-23 | Biomethodes Sa | Variants ameliores de l'interferon beta humain |
NZ580686A (en) | 2007-05-02 | 2012-11-30 | Ambrx Inc | Modified interferon beta polypeptides and their uses |
US20090304719A1 (en) | 2007-08-22 | 2009-12-10 | Patrick Daugherty | Activatable binding polypeptides and methods of identification and use thereof |
ES2536772T3 (es) * | 2007-09-21 | 2015-05-28 | The Regents Of The University Of California | El interferón dirigido demuestra potentes actividades apoptóticas y antitumorales |
US20100203009A1 (en) * | 2007-10-02 | 2010-08-12 | The Uab Research Foundation | Pathway for Th-17 Cell Development and Methods Utilizing Same |
WO2009053368A1 (en) * | 2007-10-22 | 2009-04-30 | Merck Serono S.A. | Single ifn-beta fused to a mutated igg fc fragment |
CN101939443B (zh) | 2008-02-08 | 2014-01-29 | Ambrx公司 | 经修饰瘦素多肽和其用途 |
ES2523043T3 (es) | 2008-07-23 | 2014-11-20 | Hanmi Science Co., Ltd. | Un complejo polipeptídico que comprende un polímero no peptidílico que tiene tres extremos funcionales |
ES2654387T3 (es) | 2008-07-23 | 2018-02-13 | Ambrx, Inc. | Polipéptidos G-CSF bovinos modificados y sus usos |
WO2010081173A2 (en) | 2009-01-12 | 2010-07-15 | Cytomx Therapeutics, Llc | Modified antibody compositions, methods of making and using thereof |
WO2010096838A2 (en) | 2009-02-23 | 2010-08-26 | Cytomx Therapeutics, Llc | Proproteins and methods of use thereof |
MX2011011044A (es) | 2009-04-22 | 2011-11-04 | Merck Patent Gmbh | Proteinas de fusion de anticuerpos con sitios de enlace de receptor fc neonatal (fcrn) modificados. |
US9663778B2 (en) | 2009-07-09 | 2017-05-30 | OPKO Biologies Ltd. | Long-acting coagulation factors and methods of producing same |
CA2784800A1 (en) | 2009-12-21 | 2011-07-21 | Ambrx, Inc. | Modified porcine somatotropin polypeptides and their uses |
EA201290541A1 (ru) | 2009-12-21 | 2013-05-30 | Амбркс, Инк. | Модифицированные бычьи соматотропиновые полипептиды и их применение |
DK2533634T3 (en) * | 2010-02-12 | 2016-01-25 | Biogen Ma Inc | NEURO PROTECTIVE demyelinating diseases |
US9308277B2 (en) | 2010-02-25 | 2016-04-12 | Mesoblast International Sàrl | Protease-resistant mutants of stromal cell derived factor-1 in the repair of tissue damage |
AR080993A1 (es) * | 2010-04-02 | 2012-05-30 | Hanmi Holdings Co Ltd | Formulacion de accion prolongada de interferon beta donde se usa un fragmento de inmunoglobulina |
AR083006A1 (es) | 2010-09-23 | 2013-01-23 | Lilly Co Eli | Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas |
JP6145089B2 (ja) * | 2011-06-07 | 2017-06-07 | メソブラスト インターナショナル エスエイアールエル | ストロマ細胞由来因子−1のプロテアーゼ耐性変異体を用いた、組織損傷を修復するための方法 |
SG11201401071YA (en) | 2011-10-01 | 2014-08-28 | Glytech Inc | Glycosylated polypeptide and pharmaceutical composition containing same |
CN109022465B (zh) | 2011-10-28 | 2022-04-29 | 特瓦制药澳大利亚私人有限公司 | 多肽构建体及其用途 |
JP2015520128A (ja) | 2012-04-19 | 2015-07-16 | オプコ バイオロジクス リミテッド | 長時間作用性オキシントモジュリン変異体とその作製方法 |
WO2014028502A1 (en) * | 2012-08-13 | 2014-02-20 | ImmunGene Inc. | Engineered antibody-interferon fusion molecules for treatment of autoimmune diseases |
BR122020018510B1 (pt) | 2012-11-20 | 2023-03-14 | Opko Biologics Ltd | Método para aumentar incrementalmente o tamanho hidrodinâmico de um fator de coagulação ativado viia |
WO2014089354A1 (en) | 2012-12-07 | 2014-06-12 | The Regents Of The University Of California | Cd138-targeted interferon demonstrates potent apoptotic and anti-tumor activities |
KR102073748B1 (ko) | 2013-01-31 | 2020-02-05 | 한미약품 주식회사 | 재조합 효모 형질전환체 및 이를 이용하여 면역글로불린 단편을 생산하는 방법 |
MY171183A (en) | 2013-03-29 | 2019-09-30 | Glytech Inc | Polypeptide glycosylated with sialylated sugar chain |
US11117975B2 (en) | 2013-04-29 | 2021-09-14 | Teva Pharmaceuticals Australia Pty Ltd | Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B |
UA113129C2 (xx) | 2013-04-29 | 2016-12-12 | ЗЛИТА КОНСТРУКЦІЯ АНТИТІЛО ПРОТИ CD38 З ОСЛАБЛЕНИМ ІНТЕРФЕРОНОМ АЛЬФА-2b | |
CN106967175A (zh) * | 2013-05-15 | 2017-07-21 | 复旦大学 | 长效干扰素及其制备方法和用途 |
WO2014194100A1 (en) | 2013-05-29 | 2014-12-04 | The Regents Of The University Of California | Anti-cspg4 fusions with interferon for the treatment of malignancy |
AR096891A1 (es) | 2013-07-12 | 2016-02-03 | Hanmi Pharm Ind Co Ltd | Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo |
US20150158926A1 (en) | 2013-10-21 | 2015-06-11 | Opko Biologics, Ltd. | Long-acting polypeptides and methods of producing and administering same |
RU2711322C1 (ru) | 2013-12-20 | 2020-01-16 | Ф. Хоффманн-Ля Рош Аг | Улучшенные способы получения рекомбинантного полипептида |
UA119352C2 (uk) | 2014-05-01 | 2019-06-10 | Тева Фармасьютикалз Острейліа Пті Лтд | Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину |
PE20170908A1 (es) | 2014-10-29 | 2017-07-12 | Teva Pharmaceuticals Australia Pty Ltd | VARIANTES DE INTERFERON a2b |
EP3988113A1 (en) | 2015-06-19 | 2022-04-27 | OPKO Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
RS62986B1 (sr) | 2015-06-24 | 2022-03-31 | Hoffmann La Roche | Antitela na transferinski receptor sa prilagođenim afinitetom |
TWI819458B (zh) | 2015-10-02 | 2023-10-21 | 瑞士商赫孚孟拉羅股份公司 | 雙特異性抗‐人類cd20/人類轉鐵蛋白受體抗體及使用方法 |
AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
JP7105200B2 (ja) * | 2016-05-13 | 2022-07-22 | オリオニス バイオサイエンシズ ビーブイ | 標的突然変異体インターフェロン-ベータおよびその使用 |
CN115103685A (zh) * | 2020-01-23 | 2022-09-23 | 格纳西尼有限公司 | 包含程序性细胞死亡配体1蛋白的融合蛋白及其用途 |
EP4126009A4 (en) * | 2020-04-03 | 2024-04-17 | Univ North Carolina Chapel Hill | BINDING PROTEINS FOR USE AGAINST ACE2-TARGETED VIRUSES |
Family Cites Families (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3359030A (en) * | 1966-12-16 | 1967-12-19 | Newman George | Bumper guard assembly |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4002531A (en) | 1976-01-22 | 1977-01-11 | Pierce Chemical Company | Modifying enzymes with polyethylene glycol and product produced thereby |
US4414147A (en) | 1981-04-17 | 1983-11-08 | Massachusetts Institute Of Technology | Methods of decreasing the hydrophobicity of fibroblast and other interferons |
WO1983002461A1 (en) * | 1982-01-19 | 1983-07-21 | Cetus Corp | Multiclass hybrid interferons |
US6936694B1 (en) | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
US4609546A (en) | 1982-06-24 | 1986-09-02 | Japan Chemical Research Co., Ltd. | Long-acting composition |
GB8334102D0 (en) | 1983-12-21 | 1984-02-01 | Searle & Co | Interferons with cysteine pattern |
DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
GB8412564D0 (en) * | 1984-05-17 | 1984-06-20 | Searle & Co | Structure and properties |
US4766106A (en) * | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
JP2524586B2 (ja) | 1985-06-26 | 1996-08-14 | シタス コーポレイション | ポリマ−接合を利用する医薬組成物用蛋白質の可溶化 |
US4917888A (en) | 1985-06-26 | 1990-04-17 | Cetus Corporation | Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation |
US4935233A (en) * | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
JP2514950B2 (ja) | 1986-03-10 | 1996-07-10 | エフ・ホフマン―ラ ロシユ アーゲー | 化学修飾蛋白質,その製造法および中間体 |
JPS63152393A (ja) | 1986-07-03 | 1988-06-24 | Takeda Chem Ind Ltd | グリコシル誘導体 |
US4868802A (en) * | 1986-07-28 | 1989-09-19 | Kabushiki Kaisha Toshiba | Magnetooptic recording and erasing head which performs biasing, tracking and focusing |
US4894226A (en) | 1986-11-14 | 1990-01-16 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polyproline conjugation |
US4904584A (en) | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
US4847325A (en) | 1988-01-20 | 1989-07-11 | Cetus Corporation | Conjugation of polymer to colony stimulating factor-1 |
CA1340810C (en) | 1988-03-31 | 1999-11-02 | Motoo Yamasaki | Polypeptide derivatives of human granulocyte colony stimulating factor |
WO1990005534A1 (en) | 1988-11-23 | 1990-05-31 | Genentech, Inc. | Polypeptide derivatives |
EP0401384B1 (en) | 1988-12-22 | 1996-03-13 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
US5116964A (en) * | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
US5286637A (en) | 1989-08-07 | 1994-02-15 | Debiopharm, S.A. | Biologically active drug polymer derivatives and method for preparing same |
JPH04218000A (ja) | 1990-02-13 | 1992-08-07 | Kirin Amgen Inc | 修飾ポリペプチド |
US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
AU1674292A (en) | 1991-03-15 | 1992-10-21 | Synergen, Inc. | Pegylation of polypeptides |
US5595732A (en) | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
WO1993000109A1 (en) | 1991-06-28 | 1993-01-07 | Genentech, Inc. | Method of stimulating immune response using growth hormone |
US5281698A (en) | 1991-07-23 | 1994-01-25 | Cetus Oncology Corporation | Preparation of an activated polymer ester for protein conjugation |
AU3423293A (en) | 1991-12-19 | 1993-07-19 | Baylor College Of Medicine | Pva or peg conjugates of peptides for epitope-specific immunosuppression |
ZA933926B (en) | 1992-06-17 | 1994-01-03 | Amgen Inc | Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules |
US5255519A (en) | 1992-08-14 | 1993-10-26 | Millennium Technologies, Inc. | Method and apparatus for increasing efficiency and productivity in a power generation cycle |
US5382657A (en) | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
AU5098193A (en) | 1992-09-01 | 1994-03-29 | Berlex Laboratories, Inc. | Glycolation of glycosylated macromolecules |
US5298410A (en) | 1993-02-25 | 1994-03-29 | Sterling Winthrop Inc. | Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life |
US5681811A (en) | 1993-05-10 | 1997-10-28 | Protein Delivery, Inc. | Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same |
US5359030A (en) | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
US5874075A (en) | 1993-10-06 | 1999-02-23 | Amgen Inc. | Stable protein: phospholipid compositions and methods |
US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
WO1995013090A1 (en) | 1993-11-10 | 1995-05-18 | Enzon, Inc. | Improved interferon polymer conjugates |
US5951974A (en) | 1993-11-10 | 1999-09-14 | Enzon, Inc. | Interferon polymer conjugates |
EP1090645B1 (en) | 1994-02-08 | 2005-12-07 | Amgen Inc., | Oral delivery of chemically modified proteins |
US5545723A (en) | 1994-03-15 | 1996-08-13 | Biogen Inc. | Muteins of IFN-β |
GB9415379D0 (en) * | 1994-07-29 | 1994-09-21 | Smithkline Beecham Plc | Novel compounds |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
US5738846A (en) | 1994-11-10 | 1998-04-14 | Enzon, Inc. | Interferon polymer conjugates and process for preparing the same |
CA2206852A1 (en) | 1994-12-07 | 1996-06-13 | Novo Nordisk A/S | Polypeptide with reduced allergenicity |
US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
KR0154850B1 (ko) * | 1995-10-09 | 1998-10-15 | 김광호 | 바이씨모스 및 그의 제조방법 |
US5702717A (en) | 1995-10-25 | 1997-12-30 | Macromed, Inc. | Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers |
US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
US5723125A (en) * | 1995-12-28 | 1998-03-03 | Tanox Biosystems, Inc. | Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide |
US5747639A (en) | 1996-03-06 | 1998-05-05 | Amgen Boulder Inc. | Use of hydrophobic interaction chromatography to purify polyethylene glycols |
DE69800640T2 (de) | 1997-01-29 | 2001-07-05 | Polymasc Pharmaceuticals Plc L | Pegylationsverfahren |
US5990237A (en) | 1997-05-21 | 1999-11-23 | Shearwater Polymers, Inc. | Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines |
AU751898B2 (en) | 1997-07-14 | 2002-08-29 | Bolder Biotechnology, Inc. | Derivatives of growth hormone and related proteins |
US6180095B1 (en) | 1997-12-17 | 2001-01-30 | Enzon, Inc. | Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents |
US5981709A (en) | 1997-12-19 | 1999-11-09 | Enzon, Inc. | α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same |
US5985263A (en) | 1997-12-19 | 1999-11-16 | Enzon, Inc. | Substantially pure histidine-linked protein polymer conjugates |
US5965119A (en) | 1997-12-30 | 1999-10-12 | Enzon, Inc. | Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents |
EP1061954B1 (en) | 1998-03-12 | 2004-06-09 | Nektar Therapeutics Al, Corporation | Poly(ethylene glycol) derivatives with proximal reactive groups |
PL196533B1 (pl) | 1998-04-28 | 2008-01-31 | Applied Research Systems | Sposób stopniowego przyłączania ugrupowań poli (glikolu etylenowego) (PEG) szeregowo do polipeptydu |
US6703381B1 (en) | 1998-08-14 | 2004-03-09 | Nobex Corporation | Methods for delivery therapeutic compounds across the blood-brain barrier |
CA2343094A1 (en) * | 1998-10-16 | 2000-04-27 | Biogen, Inc. | Interferon-beta fusion proteins and uses |
DK1656952T3 (da) | 1998-10-16 | 2014-01-20 | Biogen Idec Inc | Polyalkylenglycolkonjugater af interferon beta-1A og anvendelser deraf |
CN1501815A (zh) | 1999-08-27 | 2004-06-02 | 新的干扰素β-样分子 | |
CA2394980C (en) | 1999-12-22 | 2008-05-13 | Shearwater Corporation | Sterically hindered derivatives of water soluble polymers |
US20080033818A1 (en) | 2005-03-17 | 2008-02-07 | Inc2 Webcom Ltd. | Real time interactive response system and methods |
-
1999
- 1999-10-15 CA CA002343094A patent/CA2343094A1/en not_active Abandoned
- 1999-10-15 TR TR2001/01087T patent/TR200101087T2/tr unknown
- 1999-10-15 JP JP2000577197A patent/JP4761621B2/ja not_active Expired - Fee Related
- 1999-10-15 NZ NZ510559A patent/NZ510559A/en not_active IP Right Cessation
- 1999-10-15 AT AT99956574T patent/ATE327254T1/de active
- 1999-10-15 DE DE69931507T patent/DE69931507T2/de not_active Expired - Lifetime
- 1999-10-15 PT PT99956574T patent/PT1121382E/pt unknown
- 1999-10-15 ES ES99956574T patent/ES2265693T3/es not_active Expired - Lifetime
- 1999-10-15 KR KR1020017004797A patent/KR100767649B1/ko not_active IP Right Cessation
- 1999-10-15 BR BR9915548-6A patent/BR9915548A/pt not_active Application Discontinuation
- 1999-10-15 HU HU0200414A patent/HUP0200414A2/hu unknown
- 1999-10-15 EP EP99956574A patent/EP1121382B9/en not_active Expired - Lifetime
- 1999-10-15 IL IL14235099A patent/IL142350A0/xx active IP Right Grant
- 1999-10-15 AU AU13158/00A patent/AU766190B2/en not_active Ceased
- 1999-10-15 WO PCT/US1999/024200 patent/WO2000023472A2/en active IP Right Grant
- 1999-10-15 SK SK510-2001A patent/SK287491B6/sk not_active IP Right Cessation
- 1999-10-15 EE EEP200100223A patent/EE05111B1/xx not_active IP Right Cessation
- 1999-10-15 PL PL347932A patent/PL200586B1/pl not_active IP Right Cessation
- 1999-10-15 CN CNB998122130A patent/CN100480266C/zh not_active Expired - Fee Related
- 1999-10-15 EA EA200100447A patent/EA005005B1/ru not_active IP Right Cessation
- 1999-10-15 DK DK99956574T patent/DK1121382T3/da active
- 1999-10-15 MX MXPA01003790A patent/MXPA01003790A/es not_active IP Right Cessation
- 1999-10-15 CZ CZ20011330A patent/CZ300762B6/cs not_active IP Right Cessation
-
2001
- 2001-03-14 IS IS5887A patent/IS5887A/is unknown
- 2001-04-01 IL IL142350A patent/IL142350A/en not_active IP Right Cessation
- 2001-04-11 NO NO20011861A patent/NO20011861L/no unknown
- 2001-04-11 US US09/832,659 patent/US6800735B2/en not_active Expired - Fee Related
-
2002
- 2002-05-24 HK HK02103895.8A patent/HK1042098B/zh not_active IP Right Cessation
-
2004
- 2004-06-15 US US10/868,673 patent/US7527946B2/en not_active Expired - Fee Related
-
2006
- 2006-08-24 CY CY20061101194T patent/CY1105173T1/el unknown
-
2009
- 2009-03-18 US US12/406,387 patent/US20090286958A1/en not_active Abandoned
-
2010
- 2010-07-22 JP JP2010165349A patent/JP2010268810A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TR200101087T2 (tr) | İnterferon beta-füzyon proteinleri ve kullanımları | |
ES2149149T1 (es) | Proteinas de fijacion de interleuquina-18, su preparacion y utilizacion. | |
NZ503007A (en) | Conjugates that contain the homeodomain of antennapedia | |
EP1862472A3 (en) | Chlamydia protein, gene sequence and uses thereof | |
RS50364B (sr) | Modifikovani faktor viii | |
NZ330897A (en) | Human trk receptors and neurotropic factor inhibitors | |
ATE339507T1 (de) | Erythropoietin-analog-menschliches serum-albumin fusionsprotein | |
PT935607E (pt) | Proteinas de fusao de classe ii do cph soluveis monovalentes e multivalentes, e suas utilizacoes | |
EE03693B1 (et) | Isoleeritud dimeerne fibroblastide aktivatsioonivalk alfa ja selle kasutusalad | |
DE50112802D1 (de) | Peptide, deren herstellung und verwendung zur bindung von immunglobulinen | |
EP0875567A3 (de) | Myc-bindende Zinkfinger-Proteine, ihre Herstellung und ihre Verwendung | |
GB9826143D0 (en) | Tumour rejection antigens | |
EA200000875A1 (ru) | Белки, взаимодействующие с каспазой-8 | |
TR199902434T2 (tr) | Bakteriyel plazmidler. | |
GB9416536D0 (en) | Orphan receptor | |
EP1739090A3 (en) | Interferon-beta fusion proteins and uses | |
DK0946591T3 (da) | Klonede glucagon-lignende peptid-2 receptorer | |
TR200003521T2 (tr) | Yeniden-kombine-edilen insan interferonu beta-1a (IFN-beta-1a) formülasyonu. | |
DK0938555T3 (da) | Konstruktioner og komplekser af cyclin E | |
WO1995002054A3 (en) | Platelet glycoprotein v gene and uses | |
DK0540560T3 (da) | Ancrod-lignende proteiner, fremstilling og anvendelse deraf | |
CA2247998A1 (en) | Fragments of cr1 and their use | |
AU4956901A (en) | Novel human 7tm proteins and polynucleotides encoding the same | |
EP0998553A4 (en) | PROTEIN TYROSINKINASE 2 (PYK2), NUCLEIC ACIDS AND TEST PROCEDURE | |
AU2002300605A1 (en) | Compositions Comprising Conjugates of Stable, Active, Human OB Protein with Antibody FC Chain and Methods |